Emergent BioSolutions Inc. (EBS): Nasdaq/NYSE listing notice — Emergent BioSolutions receives NYSE delisting notice for delayed Q3 10-Q filing

Emergent BioSolutions Inc.

NYSE notified Emergent of noncompliance on Nov 16, 2023 due to late Q3 10-Q.
Company has six months from Nov 9, 2023 to file the 10-Q and regain compliance.
Delay stems from evaluating state deferred tax liability adjustments affecting prior periods.
No Q3 financial results provided; company still assessing impact of adjustments.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Emergent BioSolutions Inc. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

Exchange: nyse
Notice: noncompliance notice
Deficiency: late filing
Rules: 802.01E

Exact text from the filing

November 16, 2023, the New York Stock Exchange (the “NYSE”) notified Emergent BioSolutions, Inc. (“Emergent” or the “Company”) that it is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Form 10-Q”). In accordance with the NYSE Listed Company Manual, the Company has contacted the NYSE to discuss the status of its quarterly filing. On November 24, 2023, the Company issued a press release with respect to the receipt of the notice of noncompliance from

View on SEC.gov

Browse all listing & compliance notices →

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-23-000195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.